Tevogen Bio (TVGN) Competitors

$9.61 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$9.99 +0.38 (+3.94%)

As of 05/22/2026 06:53 PM Eastern

TVGN vs. BDTX, TTRX, GALT, PLYX, and KRRO

Should you buy Tevogen Bio stock or one of its competitors? MarketBeat compares Tevogen Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tevogen Bio include Black Diamond Therapeutics (BDTX), Turn Therapeutics (TTRX), Galectin Therapeutics (GALT), Polaryx Therapeutics (PLYX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry.

How does Tevogen Bio compare to Black Diamond Therapeutics?

Tevogen Bio (NASDAQ:TVGN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Tevogen Bio. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.80 beat Black Diamond Therapeutics' score of -0.15 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 940.58%. Black Diamond Therapeutics has a consensus price target of $10.00, indicating a potential upside of 338.60%. Given Tevogen Bio's higher possible upside, research analysts plainly believe Tevogen Bio is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Black Diamond Therapeutics has higher revenue and earnings than Tevogen Bio. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Black Diamond Therapeutics	$70M	1.87	$22.37M	-$0.77	N/A

Tevogen Bio's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tevogen Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.34, meaning that its share price is 234% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Tevogen Bio on 10 of the 15 factors compared between the two stocks.

How does Tevogen Bio compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Tevogen Bio (NASDAQ:TVGN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Turn Therapeutics and Turn Therapeutics both had 2 articles in the media. Tevogen Bio's average media sentiment score of 0.80 beat Turn Therapeutics' score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 55.95%. Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 940.58%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Turn Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Tevogen Bio	N/A	N/A	-472.77%

Summary

Turn Therapeutics beats Tevogen Bio on 5 of the 8 factors compared between the two stocks.

How does Tevogen Bio compare to Galectin Therapeutics?

Tevogen Bio (NASDAQ:TVGN) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Galectin Therapeutics	N/A	N/A	-164.69%

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 940.58%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 340.00%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

In the previous week, Tevogen Bio had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Tevogen Bio and 0 mentions for Galectin Therapeutics. Tevogen Bio's average media sentiment score of 0.80 beat Galectin Therapeutics' score of -1.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Positive
Galectin Therapeutics	Negative

11.7% of Galectin Therapeutics shares are held by institutional investors. 70.5% of Tevogen Bio shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tevogen Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Summary

Tevogen Bio and Galectin Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Tevogen Bio compare to Polaryx Therapeutics?

Tevogen Bio (NASDAQ:TVGN) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Tevogen Bio had 2 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for Tevogen Bio and 0 mentions for Polaryx Therapeutics. Tevogen Bio's average media sentiment score of 0.80 beat Polaryx Therapeutics' score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Positive
Polaryx Therapeutics	Neutral

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 940.58%. Polaryx Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 177.78%. Given Tevogen Bio's higher probable upside, equities research analysts plainly believe Tevogen Bio is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Tevogen Bio and Polaryx Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Tevogen Bio compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Korro Bio has a beta of 3.07, indicating that its stock price is 207% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Tevogen Bio has lower revenue, but higher earnings than Korro Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	26.20	-$117.26M	-$11.67	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

In the previous week, Korro Bio had 12 more articles in the media than Tevogen Bio. MarketBeat recorded 14 mentions for Korro Bio and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.80 beat Korro Bio's score of 0.77 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

13.2% of Korro Bio shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 70.5% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tevogen Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Tevogen Bio's return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Tevogen Bio	N/A	N/A	-472.77%

Korro Bio currently has a consensus price target of $16.71, indicating a potential upside of 43.96%. Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 940.58%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Korro Bio beats Tevogen Bio on 9 of the 16 factors compared between the two stocks.

Get Tevogen Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVGN vs. The Competition

Export

Metric	Tevogen Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.02M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-2.08	18.74	21.00	25.66
Price / Sales	N/A	323.98	558.19	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-2.15	7.09	10.40	7.14
Net Income	-$26.27M	$24.45M	$3.57B	$335.98M
7 Day Performance	-2.63%	6.38%	6.40%	4.11%
1 Month Performance	27.28%	2.43%	3.55%	2.52%
1 Year Performance	-85.33%	62.98%	34.13%	35.04%

Tevogen Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVGN Tevogen Bio	1.9434 of 5 stars	$9.61 flat	$100.00 +940.6%	-85.3%	$40.02M	N/A	N/A	3	Gap Up
BDTX Black Diamond Therapeutics	3.1242 of 5 stars	$3.00 +16.3%	$10.00 +233.3%	+13.4%	$147.84M	$70M	N/A	90	High Trading Volume
TTRX Turn Therapeutics	2.352 of 5 stars	$4.55 -7.1%	$8.00 +75.8%	N/A	$145.96M	N/A	N/A	2	High Trading Volume
GALT Galectin Therapeutics	1.7416 of 5 stars	$2.08 -5.0%	$11.00 +428.8%	+95.3%	$144.23M	N/A	N/A	9
PLYX Polaryx Therapeutics	N/A	$3.06 +10.9%	$10.00 +226.8%	N/A	$143.91M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVGN) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tevogen Bio (TVGN) Competitors

TVGN vs. BDTX, TTRX, GALT, PLYX, and KRRO

How does Tevogen Bio compare to Black Diamond Therapeutics?

Summary

How does Tevogen Bio compare to Turn Therapeutics?

Summary

How does Tevogen Bio compare to Galectin Therapeutics?

Summary

How does Tevogen Bio compare to Polaryx Therapeutics?

Summary

How does Tevogen Bio compare to Korro Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tevogen Bio (TVGN) Competitors

TVGN vs. BDTX, TTRX, GALT, PLYX, and KRRO

How does Tevogen Bio compare to Black Diamond Therapeutics?

Does the media refer more to TVGN or BDTX?

Do analysts prefer TVGN or BDTX?

Which has better valuation & earnings, TVGN or BDTX?

Is TVGN or BDTX more profitable?

Do insiders & institutionals believe in TVGN or BDTX?

Which has more risk and volatility, TVGN or BDTX?

Summary

How does Tevogen Bio compare to Turn Therapeutics?

Does the media refer more to TTRX or TVGN?

Do analysts recommend TTRX or TVGN?

Which has higher earnings & valuation, TTRX or TVGN?

Is TTRX or TVGN more profitable?

Summary

How does Tevogen Bio compare to Galectin Therapeutics?

Is TVGN or GALT more profitable?

Do analysts recommend TVGN or GALT?

Which has preferable earnings & valuation, TVGN or GALT?

Does the media refer more to TVGN or GALT?

Do insiders & institutionals have more ownership in TVGN or GALT?

Which has more volatility and risk, TVGN or GALT?

Summary

How does Tevogen Bio compare to Polaryx Therapeutics?

Does the media prefer TVGN or PLYX?

Do analysts rate TVGN or PLYX?

Which has better valuation and earnings, TVGN or PLYX?

Is TVGN or PLYX more profitable?

Summary

How does Tevogen Bio compare to Korro Bio?

Which has more risk and volatility, KRRO or TVGN?

Which has stronger earnings & valuation, KRRO or TVGN?

Does the media favor KRRO or TVGN?

Do institutionals and insiders believe in KRRO or TVGN?

Is KRRO or TVGN more profitable?

Do analysts rate KRRO or TVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools